类风湿关节炎无药持续缓解的相关临床特征:KIMERA 队列数据
该研究基于韩国早期类风湿关节炎强化管理(KIMERA)队列,分析234例中50例停用DMARDs后的临床经过。中位随访30个月,62%出现疾病复发,无药缓解维持率12、24、48个月分别为94.0%、86.7%、46.1%。停药时病程>24个月和DAS28>2.26独立关联复发。
要点
- 停用DMARDs后无药缓解维持率随时间下降,48个月降至46.1%。
- 停药时病程>24个月和DAS28>2.26独立预测疾病复发。
- 早期RA且停药时低疾病活动度者更可能维持无药缓解。
核心结论
- 在严格选择的控制良好的RA患者中,无药缓解可行,但约62%停药后复发。
- 早期RA且停药时疾病活动度较低者更可能维持无药缓解。
研究设计与样本
- 基于韩国早期类风湿关节炎强化管理(KIMERA)队列的观察性研究,共234例患者,其中50例停用DMARDs。
- 停药由患者与风湿科医生共同决策,采用Cox比例风险模型评估复发预测因素。
主要发现
- 50例停药患者中除1例使用依那西普外均使用传统合成DMARDs,中位随访30个月。
- 31例(62%)停药后出现疾病复发,无药缓解维持率12、24、48个月分别为94.0%、86.7%、46.1%。
- 复发与较长的缓解时间、初始DMARDs失败、较长病程及停药时较高疾病活动度相关(P=0.001、0.022、0.010、0.037)。
- 多变量分析中,停药时病程>24个月和DAS28>2.26独立关联疾病复发。
关键数值与推荐
- 无药缓解定义为:不使用DMARDs和糖皮质激素、DAS28<2.6、无滑膜炎证据。
- 停药时病程>24个月和DAS28>2.26为疾病复发的独立预测因素。
临床怎么用
- 对控制良好的RA患者,可考虑在医患共同决策下停用DMARDs,但需密切监测复发。
- 停药决策时应评估病程和DAS28,病程>24个月或DAS28>2.26者复发风险较高。
局限性
- 停药非随机分配,由医患共同决策决定,可能存在选择偏倚。
- 样本量较小(50例停药),随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There is limited information on treatment withdrawal in patients with rheumatoid arthritis (RA). This study investigated the clinical course after stopping disease-modifying anti-rheumatic drugs (DMARDs) in patients with well-controlled RA and the clinical features associated with disease flare. METHODS: Among patients in the Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA) cohort, discontinuation of DMARDs was determined by a shared decision between patient and rheumatologist. Drug-free remission was defined as (1) non-use of DMARDs and corticosteroids, (2) Disease Activity Score in 28 joints (DAS28) <2.6, and (3) no evidence of synovitis. The maintenance rate of drug-free remission and the predictors for flare were evaluated using Cox proportional hazard models. RESULTS: Of 234 patients, 50 patients discontinued DMARDs. All but one using etanercept were treated with conventional synthetic DMARDs. The median follow-up duration was 30 months, and 31 patients (62%) experienced disease flare after stopping DMARDs. The maintenance rate of drug-free remission was 94.0%, 86.7%, and 46.1% at 12, 24, and 48 months, respectively. Disease flare was correlated with longer time to remission, failure of initial DMARDs, and longer duration of disease and higher disease activity at DMARD withdrawal (P = 0.001, 0.022, 0.010 and 0.037, respectively). In multivariate analyses, longer duration of disease (>24 months) and higher disease activity (DAS28 >2.26) at DMARD withdrawal was independently associated with disease flare. CONCLUSION: Drug-free remission was feasible in selected patients with well-controlled RA. Patients with early RA and lower disease activity at DMARD withdrawal are more likely to maintain the drug-free remission.
引用
- Jung SM, Pyo JY, Lee SW, et al. Clinical characteristics associated with drug-free sustained remission in patients with rheumatoid arthritis: Data from Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA). Semin Arthritis Rheum. 2020. PMID: 32241617. doi:10.1016/j.semarthrit.2020.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。